recombinant exendin-4 (Uni-E4) / Uni-Bio Sci - LARVOL DELTA

Addressing challenges along the 'access cascade' for new TB regimens. (PubMed, IJTLD Open) - "Our analysis is based on: i) stakeholder engagement efforts undertaken in the context of UNITE4TB (a global clinical trial consortium for development of new TB drugs and regimens), ii) the outcomes of a special session of the UNITE4TB Annual Meeting 2024 in which representatives from several key stakeholder groups (pharmaceutical, clinical, research, regulatory, oversight, and advocacy) spoke on the topic of access to new TB regimens; and iii) a review of the literature. We propose a model for an 'access cascade' detailing the necessary steps from early research and development to the introduction of new regimens into clinical care. We then determined potential bottlenecks that might impede equitable access to new TB regimens globally, and conclude with recommended actions for stakeholders to take to overcome or mitigate the effects of these bottlenecks."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

The role of the UNITE4TB Young Investigators Group in empowering early career researchers through mentorship, capacity building, and innovation. (PubMed, IJTLD Open) - No abstract available

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Exposure-QTc modeling of bedaquiline, pretomanid, and clofazimine in adults with tuberculosis. (PubMed, Antimicrob Agents Chemother) - "For patients aged 70 years with non-black ancestry, at risk of increased BDQ exposure, simulations showed that 39.1% had a drug-induced QT change >30 ms after the loading period; this was 29.4% for following BDQ 400 mg daily regimen (part of UNITE4TB program). We present a joint concentration-QT model of BDQ, Pa, and CFZ. The competitive interaction model serves as a tool to predict possible combined exposure-induced QT prolongation of these drugs in different dosing regimen and identify patients at high risk of significant QT-prolongation."

Journal • Cardiovascular • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Accessible Type 2 diabetes medication through stable expression of Exendin-4 in Saccharomyces cerevisiae. (PubMed, Front Syst Biol) - "In this study, experimental models for recombinant Exendin-4 protein production were designed in both Escherichia coli and Saccharomyces cerevisiae. Protein expression in the chromosomally integrated S. cerevisiae strain was observed at the expected size of Exendin-4 and confirmed by immunoassay. This provides a foundation for the use of this Generally Regarded as Safe organism as an affordable treatment for Type 2 diabetes that can be propagated, prepared, and distributed locally."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Candidate anti-tuberculosis medicines and regimens under clinical evaluation. (PubMed, Clin Microbiol Infect) - "A large number of potential anti-TB candidate medicines and innovations in clinical trial design for the evaluation of regimens, rather than single medicines, provide hope for improvements in the treatment of TB."

Journal • Review • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

415: UNITE4TB: tuberculosis renewed European Union project (ERS 2023) - "Aims: to explain how to use and discuss the methods used to diagnose tuberculosis (TB) and identify resistance; to describe the different drugs and regimens being studied for TB treatment; to explain the advances and challenges in the development of biomarkers; to explain the importance of treatment adherence and the different interventions in use."

Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

"@IgorStojkov_ @DerryMercer @GeraldineJoanny @YojanaGadiya @FernowJosepine @RaquelAFDuarte @SwissButcher74 @IHIEurope @EFPIA @AllianceBEAM @EuropeVaccine @TRIC_TB @UNITE4TB @AMR_Combine @UU_University @lygature @GSK @Evotec @JanssenGlobal @LMU_Muenchen @Bioversys" (@AMRAccelerator)

Clinical

"Deep empathy @fabian_theis quoting @EricTopol at the #UNITE4TB #ERS webnar on AI and Tuberculosis" (@otavio_ranzani)

Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

"Presenting Work Package Biomarkers at the @UNITE4TB Project Steering Committee in Tres Cantos, Madrid, Spain. Thank you @GSK for hosting us! #tuberculosis #biomarkers" (@biosquirrel_)

Biomarker • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

"UNITE4TB partners, please help spread the word: @ISPUP, @LaStatale, @lygature, @EuroRespSoc, @TBAlliance, @TBnet_EU, @LMU_Uniklinikum, @DZIF_, @GSK, @JNJNews, @EFPIA, @radboudumc, @OUCRU_Programme, @taskapplied, @FINDdx, @EuropeanLung, @CPathInstitute, @kncvtbc, @UCSF_CTB" (@UNITE4TB)

Production of active Exendin-4 in Nicotiana benthamiana and its application in treatment of type-2 diabetics. (PubMed, Front Plant Sci) - "In this study, we report that the GLP-1 analogue recombinant Exendin-4 (Exdn-4) can be produced at a high level in Nicotiana benthamiana, with an estimated yield of 50.0 µg/g fresh biomass. Moreover, Exdn-4 without any extra residues was produced from BGC : Exdn-4 bound onto MCC beads by treating with enterokinase. Plant-produced Exdn-4 (Exendin-4) was as effective as chemically synthesized Exendin-4 in glucose-induced insulin secretion (GIIS) from mouse MIN6m9 cells a pancreatic beta cell line."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

"#StrongerTogether ! We're proud @IHIEurope @AMRAccelerator project @UNITE4TB is fighting to #ENDTB 💪💊" (@AMR_Combine)

"Unite4Truth deep dive: Bill Gates and the use of "Insecticide Cures" for fake diseases: https://t.co/AoS6IxbXe3" (@PodcastBill)

"Hello @UNITE4TB, welcome to Twitter! 👋🏻" (@JensJot)

"El Dr Barros (@GSK) presenta l’estudi #UNITE4 que compta amb finançament de la @EU_Commission a través del #IMI2 #TallerTB21 @TB_UITB" (@tbexperimental)

UNITE4TB: a new consortium for clinical drug and regimen development for TB. (PubMed, Int J Tuberc Lung Dis) - No abstract available

Clinical • Journal

"Intriguing during these tumultuous times... @Roche @DrRomie @purviparwani @pjain @MattSakumoto @Karthik28930366 #unite4india" (@MamtaSwa)